-+ 0.00%
-+ 0.00%
-+ 0.00%

Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis

Benzinga·11/05/2026 13:02:15
Listen to the news

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3. The study is designed to evaluate the efficacy, safety, and tolerability of once-daily ZORYVE® (roflumilast) cream 0.3% for the treatment of individuals ages 6 and older with moderate to severe atopic dermatitis.